Arbutus Biopharma (ABUS) Leases (2019 - 2024)
Arbutus Biopharma (ABUS) has disclosed Leases for 6 consecutive years, with $1.0 million as the latest value for Q4 2024.
- Quarterly Leases fell 25.99% to $1.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2024, down 25.99% year-over-year, with the annual reading at $1.0 million for FY2024, 25.99% down from the prior year.
- Leases hit $1.0 million in Q4 2024 for Arbutus Biopharma, down from $1.1 million in the prior quarter.
- In the past five years, Leases ranged from a high of $2.7 million in Q1 2020 to a low of $1.0 million in Q4 2024.
- Historically, Leases has averaged $1.9 million across 5 years, with a median of $1.9 million in 2022.
- Biggest five-year swings in Leases: fell 11.24% in 2020 and later decreased 25.99% in 2024.
- Year by year, Leases stood at $2.4 million in 2020, then dropped by 13.01% to $2.1 million in 2021, then dropped by 16.63% to $1.7 million in 2022, then decreased by 18.81% to $1.4 million in 2023, then fell by 25.99% to $1.0 million in 2024.
- Business Quant data shows Leases for ABUS at $1.0 million in Q4 2024, $1.1 million in Q3 2024, and $1.2 million in Q2 2024.